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 Abstract 
 Background: Adequate control of plasma phosphate without phosphate binders is difficult to 
achieve on a thrice-weekly haemodialysis schedule. The use of quotidian nocturnal dialysis is 
effective but not practical in the in-centre setting. This quality improvement project was set up 
as an exercise allowing the evaluation of small-solute clearance by combining convection with 
extended-hour dialysis in a thrice-weekly hospital setting.  Methods: A single-centred, pro-
spective analysis of patients’ electronic records was performed from August 2012 to July 2014. 
The duration of haemodiafiltration was increased from a median of 4.5 to 8 h. Dialysis adequa-
cy, biochemical parameters and medications were reviewed on a monthly basis. A reduction in 
plasma phosphate was anticipated, so all phosphate binders were stopped.  Results: Since in-
ception, 14 patients have participated with over 2,000 sessions of dialysis. The pre-dialysis 
phosphate level fell from a mean of 1.52 ± 0.4 to 1.06 ± 0.1 mmol/l (p < 0.05). The average 
binder intake of 3.26 ± 2.6 tablets was eliminated. A normal plasma phosphate range has been 
maintained with increased dietary phosphate intake and no requirement for intradialytic phos-
phate supplementation.  Conclusion: Phosphate control can be achieved without the need for 
binders or supplementation on a thrice-weekly in-centre haemodiafiltration program. 
 © 2015 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Patients undergoing conventional dialysis 3 times at 4-hour sessions per week exhibit an 
excess mortality rate 4 times higher than that of the general population for patients under 30 
years, and 6 times that of the general population for patients above 65 years  [1] . This increased 
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mortality has been attributed to a low dialysis dose  [2] , but two large randomised controlled 
trials have failed to show any survival benefit for patients receiving a larger dialysis dose
 [3, 4] .
 In an effort to improve outcomes, multiple treatment schedules have been utilised. 
On-line haemodiafiltration (OL-HDF), which combines diffusion and convection, has grown 
in popularity over the last 20 years. This provides enhanced clearance of toxins  [5, 6] , 
increased haemodynamic stability  [7] and better quality of life  [8] . The use of more frequent 
dialysis has also been shown to be beneficial  [9, 10] . The advantages in bone mineral profile 
 [11, 12] , blood pressure (BP) control  [13] , patient experience and improved mortality  [14] in 
programs with extended-hour dialysis have been well demonstrated. This is often not an 
acceptable alternative for patients, and few of the studies of extended-hour dialysis are based 
in a centre, as the majority of patients in these studies undertake nocturnal dialysis at home. 
The use of convective therapy in combination with extended-hour dialysis has been shown 
to be beneficial  [15] but is not frequently described.
 We have established a program of thrice-weekly 7- to 8-hour nocturnal OL-HDF in our 
centre in the belief that this will improve quality of dialysis by combining convection with 
extended-hour treatment. This seemed an excellent compromise for patients who could not 
have home dialysis but wanted to benefit from having extended hours. The frequency was 
kept at thrice weekly due to patient preference. The program initially started with 10 patients, 
and over a 2-year period our patients have had over 2,000 sessions of OL-HDF.
 Methods 
 Data were collected prospectively from patients’ electronic records over a 2-year period. 
Patients were self-selected with no stipulated exclusion criteria apart from patients needing 
to have their own transport due to the timing of commencement and cessation of treatment. 
Only 10 patients initially came forward.
 Patient Characteristics 
 During the study period, 14 patients (13 male and 1 female) started nocturnal OL-HDF. 
The mean age was 45.2 ± 13.1 years (range 23.8–66.2), and renal replacement treatment 
vintage was 42.34 ± 40.62 months (range 6.61–116.94). All patients were on regular OL-HDF 
for at least 6 months [mean 30.93 ± 27.68 (range 6.67–93.44)] prior to conversion to the 
nocturnal regime.
 The cause of end-stage renal disease was pyelonephritis/interstitial nephritis, Alport’s 
disease, haemolytic uremic syndrome, reflux nephropathy, membranous nephropathy and 
renovascular disease (1 patient each); adult polycystic kidney disease, IgA nephropathy, 
rapid progressive glomerulonephritis and unknown causes (2 patients each). All patients 
except one had a native arteriovenous fistula. Drop-out reasons prior to 12 months were 
planned change in modality (1 patient), transplantation (3 patients) or lifestyle choice (1 
patient).
 Ethical approval was not sought, as this study was a part of quality improvements to 
services.
 Nocturnal Treatment Regime 
 Patients on standard 4- to 5-hour thrice-weekly OL-HDF were switched to 7- to 8-hour 
thrice-weekly nocturnal OL-HDF. Patients were dialysed using a Fresenius 5008 machine and 
a Gambro Polyflux dialyser, without reuse. The blood flow (Qb) was reduced to 200 ml/min, 
and dialysate flow (Qd) was reduced to 300 ml/min. All patients continued on post-dilution 
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OL-HDF with a dialysate calcium concentration of 1.75 mmol/l and potassium adjusted 
according to pre-dialysis levels. The dialysate bicarbonate concentration was reduced to 
prevent the development of alkalosis, and anticoagulation was increased by 50%.
 Review of Biochemical and Clinical Parameters 
 A monthly review of dialysis adequacy, electrolytes and haemoglobin (Hb) measure-
ments was carried out. The baseline biochemical parameters were calculated from the 
averages of the last 3 months during standard thrice-weekly 4- to 5-hour OL-HDF. Routine 
samples (before and after dialysis) were collected on the first weekday of the short intradia-
lytic gap of the month. Small-solute clearance was assessed using a standard Kt/V equation 
(Std Kt/V)  [16] with mineral bone disease monitored by plasma phosphate and calcium 
levels. A reduction in plasma phosphate was expected, so all phosphate binders were stopped. 
All patients were assessed by a qualified renal dietician and advised to relax their phosphate 
restriction.
 Samples for ferritin and vitamin B 12 were analysed every 3 months and for parathyroid 
hormone (PTH) and β-2 microglobulin every 6 months. Doses of intravenous iron, erythro-
poietin (darbepoetin-α) and BP medication use were recorded. Changes in medication were 
at the discretion of the responsible physician.
 Average readings of clinical parameters, i.e. BP, weight and hydration, were assessed 
using a multi-channel bioimpedance Fresenius ® body mass composition monitor and an-
alysed with Fluid Management Tool software version 3.3.0.1637 on a quarterly basis.
 Statistical Analysis 
 Data were recorded prospectively for a period of 24 months and included in the analysis 
where 12 months or more of data were available. These data were analysed using SPSS 
software package version 17. A repeated measure of analysis of variance was performed 
with respect to baseline. Each patient served as his/her own control. As the sample size was 
small, non-parametric statistics were used to compare readings at 24 months with baseline 
using the Wilcoxon signed-rank test. A value of p < 0.05 was considered statistically signif-
icant.
 Results 
 Bone Profile 
 The pre-dialysis phosphate level fell from a mean of 1.52 ± 0.41 to 1.21 ± 0.2, 1.26 ± 0.45, 
1.28 ± 0.32 and 1.06 ± 0.13 mmol/l at 3, 6, 9 and 24 months, respectively (p < 0.05 at 24 
months;  table 1 ;  fig. 1 ). The use of binders dropped from an average of 3.26 ± 2.63 tablets to 
zero (p < 0.05;  table 1 ;  fig. 1 ). None of the patients have required recommencement of a phos-
phate binder or supplementation during dialysis due to low phosphate levels.
 Calcium levels were non-significantly raised at 24 months, which theoretically could lead 
to a positive calcium balance. PTH, however, fell from 39.24 ± 31.4 pmol/l at baseline to 23.97 
± 27.1 and 26.13 ± 12.6 pmol/l at 12 and 24 months, respectively (p < 0.05; data not shown). 
This failed to reach significance when the patient on cinacalcet was excluded (p = 0.08 at 6 
months and p = 0.07 at 12 and 24 months;  table 2 ). None of the patients has required a para-
thyroidectomy.
 Small-Solute Clearance 
 Std Kt/V increased from 2.37 ± 0.21 (range 1.93–2.65) to 2.68 ± 0.16 (range 2.52–2.92) 
at 24 months, with p < 0.05 at 3, 6, 9 and 24 months compared to baseline ( table 1 ;  fig. 2 ).
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 Table 1.  Change from thrice-weekly OL-HDF (4 – 5 h) to thrice-weekly nocturnal HDF (7 – 8 h)
Baseline 3 months
(n = 9)
6 months
(n = 9)
9 months
(n = 9)
24 months
(n = 5)
Time, min 277.22 ± 25.80 474.26 ± 9.58a 472.52 ± 7.92a 476.85 ± 5.99a 466.60 ± 13.68c
Volume, l 22.54 ± 3.91 27.53 ± 3.19b 27.25 ± 3.34b 28.26 ± 3.79a 28.85 ± 2.22c
URR 0.76 ± 0.08 0.84 ± 0.05a 0.83 ± 0.06a 0.83 ± 0.05b 0.85 ± 0.04c
Std Kt/V 2.37 ± 0.21 2.68 ± 0.18a 2.62 ± 0.25b 2.61 ± 0.19b 2.68 ± 0.16c
Corr. Ca, mmol/l 2.34 ± 0.22 2.37 ± 0.17 2.41 ± 0.15 2.39 ± 0.14 2.48 ± 0.19
PO4, mmol/l 1.52 ± 0.41 1.21 ± 0.20 1.26 ± 0.45 1.28 ± 0.32 1.06 ± 0.13c
PO4 binders 3.26 ± 2.63 0.00 ± 0.00a 0.00 ± 0.00a 0.00 ± 0.00a 0.00 ± 0.00c
Hb, g/dl 11.58 ± 1.35 11.55 ± 0.97 11.19 ± 1.58 12.10 ± 0.72 11.96 ± 0.47
Ferritin, μg/l 492.85 ± 295.04 463.17 ± 305.99 423.00 ± 247.00 342.33 ± 152.44 321.40 ± 117.27
EPO, weekly dose 21.85 ± 21.61 12.96 ± 16.11 18.52 ± 16.92 15.74 ± 13.67 15.00 ± 8.66
Iron dose, mg/week 50.93 ± 28.40 29.63 ± 32.30b 26.85 ± 23.12b 22.22 ± 23.20b 45.00 ± 32.60
Vitamin B12, ng/l 440.07 ± 108.51 480.56 ± 138.48 5 20 ± 141.55 429.67 ± 128.71 331.80 ± 37.35
Overhydration, l 1.53 ± 2.96 1.31 ± 1.48 1.48 ± 1.21 1.08 ± 1.21 1.81 ± 2.44
Systolic BP, mm Hg 146.63 ± 21.77 139.52 ± 26.68 137.26 ± 25.18 140.30 ± 30.22 137.47 ± 17.30
Diastolic BP, mm Hg 75.04 ± 12.84 70.20 ± 15.03 67.07 ± 20.09 70.94 ± 17.16 69.40 ± 13.84
BP medications 1.31 ± 1.04 0.70 ± 1.31b 0.56 ± 1.33b 0.67 ± 1.32b 0.60 ± 0.89c
 Values are means ± standard deviations. Corr. Ca = Corrected calcium; EPO = erythropoietin; PO4 = 
phosphate; URR = urea reduction ratio.
a p < 0.01, with respect to baseline; repeated-measures analysis of variance (ANOVA). b p < 0.05, with 
respect to baseline; ANOVA. c p < 0.05, Wilcoxon signed-rank test.
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 Fig. 1. Significant reduction in the use of phosphate binders (p < 0.05 at 3, 6, 9 and 24 months) and phosphate 
levels (p < 0.05 at 24 months) on conversion from standard 4-hour HDF to nocturnal 8-hour HDF. Means ± 
standard deviations are given.  * n = 9,  † n = 5, where n is the number of patients. 
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 Middle-Molecule Clearance 
 β-2 microglobulin levels showed no significant change. Baseline levels were 23.34 ± 9.19 
mg/l and levels at 6, 12 and 24 months were 20.88 ± 5.99, 20.99 ± 5.21 and 24.09 ± 3.13 mg/l, 
respectively ( table 2 ).
 Filtration Volume 
 The OL-HDF substitution volume increased from 22.53 ± 3.91 litres per session to 27.53 
± 3.19 litres at 3 months and 27.25 ± 3.34, 28.26 ± 3.79 and 28.85 ± 2.22 litres at 6, 9 and 24 
months, respectively (p < 0.05 at 3, 6, 9 and 24 months).
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 Fig. 2. Significant improvement in the dialysis dose delivered (Std Kt/V) on conversion from standard 4-hour 
HDF to nocturnal 8-hour HDF at 3, 6, 9, 12 and 24 months. Means ± standard deviations are given.  * n = 9, 
 † n = 5, where n is the number of patients. 
 Table 2. Changes in β-2 microglobulin and PTH levels on changing from thrice-weekly OL-HDF (4 – 5 h) to 
thrice-weekly nocturnal OL-HDF (7 – 8 h)
Baseline 6 months 12 months 24 months 
β2m, mg/dl 23.34 ± 9.19 20.88 ± 5.99
(n = 9)
20.99 ± 5.21
(n = 9)
24.09 ± 3.13
(n = 5)
PTH, pmol/l 30.52 ± 14.55 21.93 ± 22.53
(n = 7)
15.45 ± 11.84
(n = 7)
20.84 ± 4.82
(n = 4)
Values are means ± standard deviations. PTH data of the patient on cinacalcet were omitted. No significant 
reduction was observed over time, although changes are almost significant (p = 0.08 at 6 months, p = 0.07 at 
12 and 24 months). There was no significant change for β-2 microglobulin.
β2m = β-2 microglobulin.
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 BP, Fluid Status and Antihypertensive Medications 
 BP reduction and changes in overhydration status did not reach statistical significance, 
but the use of antihypertensive medications decreased from 1.31 ± 1.04 to 0.6 ± 0.89 tablets 
at 24 months (p < 0.05).
 Haematological Parameters and Erythropoietin Dose 
 Intravenous iron use showed a significant decrease from baseline 50.93 ± 28.4 to 29.63 
± 32.3, 26.85 ± 23.12 and 22.22 ± 23.2 mg/week at 3, 6 and 9 months, respectively, but not at 
24 months (45 ± 32.6 mg/week). Erythropoietin use decreased but did not reach statistical 
significance. Hb levels did not change significantly.
 Discussion 
 Thrice-weekly extended-hour nocturnal OL-HDF seems to be an excellent alternative to 
current modalities of dialysis. It achieves targets for small-solute clearance and mineral bone 
disease with elimination of phosphate binders and no dietary phosphate restrictions. It has 
been accepted and well tolerated by patients. 
 The unique finding of this study is the complete elimination of phosphate binders 
without the requirement for intradialytic phosphate supplementation. Phosphate control 
with dialysis alone was first described in 1998 where patients were converted from conven-
tional thrice-weekly dialysis to dialysis 6 nights weekly. Normal phosphate levels were 
achieved at 5 months despite a 50% increase in phosphate intake in diet. The blood flow 
rate was 300–350 ml/min and the dialysate flow rate 500 ml/min  [11] . A recent paper by 
Maduell et al.  [15] to evaluate the beneficial effects of alternate-day nocturnal OL-HDF 
reported a reduction in serum phosphorus from 4.93 ± 1.5 mg/dl (1.59 ± 0.48 mmol/l) to 
3.74 ± 1 mg/dl (1.20 ± 0.32 mmol/l) at 12 months. Phosphate binders were reduced, but not 
eliminated, and intradialytic supplementation was needed in 55% patients. Blood flows 
were 400 ml/min and dialysate flows were 500 ml/min. The Australian experience of 
converting patients from a conventional regime to home nocturnal 6- to 9-hour sessions 
3.5–4 times weekly resulted in a significant reduction in phosphate levels, again with a 
reduction in phosphate binder consumption but with 22.7% patients needing supplemen-
tation. Blood flow was 200–250 ml/min with a dialysate flow of 500 ml/min  [17] . A recent 
study by a Dutch group comparing conventional [4-hour haemodialysis (HD) and HDF] and 
extended (8-hour HD and HDF) dialysis reported ‘treatment time’ as a major determinant 
of small-molecule clearance and haemodynamic stability. The total solute removal (urea, 
uric acid, creatinine and phosphate) was higher in the longer-duration treatments, with no 
difference noted in the treatment modalities (HD vs. HDF). Acute effects were only studied 
in this randomised cross-over trial. Blood flow was 300 ml/min and dialysate flow 600 ml/
min in all study sessions  [18] . The improvement in small-solute clearance is consistent with 
other published reports  [15, 19] . The normal serum phosphate without the need for supple-
mentation, previously not reported, could either be due to the lower dialysate and blood 
flows employed or to the reduced frequency of HDF 3 times per week. We, however, could 
not demonstrate a reduction in middle-molecule levels (β-2 microglobulin). This may be 
due to the high substitution volumes utilised at baseline in these patients, but it suggests 
that dialysis duration per se is a less important factor in achieving higher β-2 microglobulin 
clearance.
 Other biochemical parameters such as Hb did not change, though there was a trend 
towards a reduction in iron and erythropoietin doses. This lowering in erythropoietin doses 
might have been achieved if iron doses had not been decreased.
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 Charra et al.  [13] in France have reported one of the lowest mortality and morbidity 
statistics in dialysis patients. Absence of cardiovascular complications and good BP was 
achieved with maintenance of dry weight, a low-salt diet and no antihypertensive drugs. 
Despite following a similar regime, our BP lowering did not reach statistical significance. 
There was a reduction in antihypertensive medications during the study without change in 
BP, which may suggest overall better BP control. Overhydration ( table 1 ) from a high salt 
intake contributing to extracellular volume expansion may explain why a significant reduction 
in BP was not demonstrated.
 We noted a significantly higher substitution volume following transfer to the nocturnal 
program. Theoretically, this may confer a survival advantage in the longer term, as implied 
by a post hoc sub-analysis of data from two recent randomised controlled trials which showed 
a lower mortality rate with higher substitution volumes of >17.4 and >21.95 litres per session 
 [3, 4] .
 Limitations 
 Our study has limitations due to the small patient numbers and being observational in 
nature. All patients were self-selected, thus, undoubtedly, more motivated and may have less 
co-morbidities than conventional dialysis patients. Post-dialysis phosphate monitoring was 
not conducted. No food charts or 24-hour urine collections were formally recorded to assess 
increased dietary intake of phosphate, but it is difficult to imagine that patients advised to 
follow a relaxed diet would continue to adhere to phosphate restriction. Residual renal 
function was not measured, but as each patient acted as their own control, it is unlikely that 
this would contribute to the benefits seen. Finally, we do not have a parallel comparator 
group comparing HD and HDF.
 Conclusion 
 Nocturnal thrice-weekly in-centre OL-HDF is a practical alternative and is superior to 
conventional OL-HDF in terms of small-solute clearance and control of phosphate and allows 
a reduction in medication. It has the potential to improve outcomes, but this as yet remains 
unproven. It has been well tolerated by this patient group and should be considered as a 
treatment alternative for patients receiving hospital-based HD therapy.
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